{"id":35970,"date":"2014-05-23T09:36:04","date_gmt":"2014-05-23T14:06:04","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=35970"},"modified":"2014-05-23T18:06:40","modified_gmt":"2014-05-23T22:36:40","slug":"imiquimod-estimulador-de-la-respuesta-inmune-en-las-neoplasias-cutaneas","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/35970","title":{"rendered":"Imiquimod: Estimulador de la respuesta inmune en las neoplasias cut\u00e1neas"},"content":{"rendered":"<p><em><strong>Dra. Martha Mini\u00f1o<\/strong><\/em><br \/>\n<span style=\"color: #999999;\"><em> Rep\u00fablica Dominicana<\/em><\/span><\/p>\n<p><em>Texto de Charla dictada por la Prof Dra. Martha Mini\u00f1o en el congreso de Radla 2014 en Chile<\/em><\/p>\n<p><!--more--><\/p>\n<p><strong>Imiquimod: Conclusiones<\/strong><\/p>\n<ul>\n<li>El imiquimod posee efectos antivirales &amp; antitumorales seg\u00fan la patolog\u00eda.<\/li>\n<li>Se reportan pocos efectos adversos, a excepci\u00f3n de la irritaci\u00f3n.<\/li>\n<li>Es aplicable en ni\u00f1os.<\/li>\n<li>Puede ser empleado en m\u00faltiples patolog\u00edas como terapia de primera l\u00ednea.<\/li>\n<li>Aplicable como terapia de segunda l\u00ednea cuando el tratamiento convencional falla.<\/li>\n<li>En muchos casos permite reducir la cirug\u00eda en pacientes de riesgo.<\/li>\n<li>Tambi\u00e9n permite disminuir el riesgo de deformidad.<\/li>\n<li>Es aplicable en sitios anat\u00f3micos dif\u00edciles para la cirug\u00eda.<\/li>\n<li>Puede ser empleado en conjunci\u00f3n con otros tratamientos.<\/li>\n<li>Precisa de cierto grado de inflamaci\u00f3n para lograr sus efectos.<\/li>\n<li>Todav\u00eda precisa de mayores estudios.<\/li>\n<\/ul>\n<p><a href=\"http:\/\/1drv.ms\/1m1xZkE\" target=\"_blank\">Clic aqu\u00ed para leer el art\u00edculo completo &gt;&gt;<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dra. Martha Mini\u00f1o Rep\u00fablica Dominicana Texto de Charla dictada por la Prof Dra. Martha Mini\u00f1o en el congreso de Radla 2014 en Chile<\/p>\n","protected":false},"author":67,"featured_media":35971,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[553,11],"tags":[],"class_list":["post-35970","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-aportes-del-comite-editorial","category-secciones-de-colaboradores"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/35970","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=35970"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/35970\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media\/35971"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=35970"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=35970"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=35970"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}